🚨 NEW research⚕️ 🩺
dlvr.it/TVHHMp
Hasan et al. conducted a randomized controlled trial with patients receiving spironolactone (100 mg or 200 mg) or placebo, measuring endpoint of working memory performance after three weeks of treatment.
dlvr.it
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trial - Communications Medicine
Hasan, Leucht et al. undertook a drug repurposing trial evaluating the mineralocorticoid antagonist spironolactone as a treatment for cognitive impairment in people with schizophrenia. The primary analysis yielded negative results, but subsequent sensitivity analyses suggest this approach could potentially be a treatment option for schizophrenia.